Dr Ralf Hoffmann
- Honorary Senior Lecturer (School of Psychology & Neuroscience)
                        email: 
                        Ralf.Hoffmann@glasgow.ac.uk
                    
FBLS - Integrated Biology, West Medical Building
Publications
2024
    
    Gulliver, Chloe, Busiau, Tara, Byrne, Ashleigh, Findlay, Jane E., Hoffmann, Ralf and Baillie, George ORCID: https://orcid.org/0000-0003-2469-6316
  
(2024)
  
cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
    
    Molecular Oncology, 18(3),
	  pp. 707-725.
     
    
    (doi: 10.1002/1878-0261.13572)
    (PMID:38126155) 
    (PMCID:PMC10920091) 
  
  
2023
    
    Gulliver, Chloe, Huss, Sebastian, Semjonow, Axel, Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation, and alterations in DNA repair: implications for therapeutic strategies.
    
    British Journal of Cancer, 129(9),
	  pp. 1462-1476.
     
    
    (doi: 10.1038/s41416-023-02417-5)
    (PMID:37740039) 
    (PMCID:PMC10628190) 
  
  
    
    Gulliver, Chloe, Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region.
    
    Future Science OA, 9(9),
	 
     
    
    (doi: 10.2144/fsoa-2023-0064)
    (PMID:37752916) 
    (PMCID:PMC10518809) 
  
  
    
    Parsons, Emma C. ORCID: https://orcid.org/0000-0003-4693-2172, Baillie, George S. 
ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
Revisiting the roles of cAMP signalling in the progression of prostate cancer.
    
    Biochemical Journal, 480(20),
	  pp. 1599-1614.
     
    
    (doi: 10.1042/BCJ20230297)
     
     
  
  
    
    Gulliver, Chloe, Huss, Sebastian, Semjonow, Axel, Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes.
    
    Cancers, 15(1),
	 
      262.
    
    (doi: 10.3390/cancers15010262)
    (PMID:36612262) 
    (PMCID:PMC9818961) 
  
  
2022
    
    Gulliver, Chloe, Hoffmann, Ralf and Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316
  
(2022)
  
Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    
    International Journal of Biochemistry and Cell Biology, 147,
	 
      106230.
    
    (doi: 10.1016/j.biocel.2022.106230)
    (PMID:35609768) 
     
  
  
2021
    
    Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316, Gulliver, Chloe and Hoffmann, Ralf
  
(2021)
  
The enigmatic helicase DHX9 and its association with the hallmarks of cancer.
    
    Future Science OA, 7(2),
	 
      FSO650.
    
    (doi: 10.2144/fsoa-2020-0140)
    (PMID:33437516) 
    (PMCID:PMC7787180) 
  
  
2018
van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)
2015
    
    Byrne, Ashleigh M., Elliott, Christina ORCID: https://orcid.org/0000-0002-2838-8612, Hoffmann, Ralph and Baillie, George S. 
ORCID: https://orcid.org/0000-0003-2469-6316
  
(2015)
  
The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
    
    FEBS Letters, 589(6),
	  pp. 750-755.
     
    
    (doi: 10.1016/j.febslet.2015.02.004)
    (PMID:25680530) 
    (PMCID:PMC4346272) 
  
  
2014
    
    Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. ORCID: https://orcid.org/0000-0003-2469-6316 and Houslay, M.D.
  
(2014)
  
The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.
    
    British Journal of Cancer, 110(5),
	  pp. 1278-1287.
     
    
    (doi: 10.1038/bjc.2014.22)
     
     
  
  
Articles
    
    Gulliver, Chloe, Busiau, Tara, Byrne, Ashleigh, Findlay, Jane E., Hoffmann, Ralf and Baillie, George ORCID: https://orcid.org/0000-0003-2469-6316
  
(2024)
  
cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
    
    Molecular Oncology, 18(3),
	  pp. 707-725.
     
    
    (doi: 10.1002/1878-0261.13572)
    (PMID:38126155) 
    (PMCID:PMC10920091) 
  
  
    
    Gulliver, Chloe, Huss, Sebastian, Semjonow, Axel, Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation, and alterations in DNA repair: implications for therapeutic strategies.
    
    British Journal of Cancer, 129(9),
	  pp. 1462-1476.
     
    
    (doi: 10.1038/s41416-023-02417-5)
    (PMID:37740039) 
    (PMCID:PMC10628190) 
  
  
    
    Gulliver, Chloe, Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region.
    
    Future Science OA, 9(9),
	 
     
    
    (doi: 10.2144/fsoa-2023-0064)
    (PMID:37752916) 
    (PMCID:PMC10518809) 
  
  
    
    Parsons, Emma C. ORCID: https://orcid.org/0000-0003-4693-2172, Baillie, George S. 
ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
Revisiting the roles of cAMP signalling in the progression of prostate cancer.
    
    Biochemical Journal, 480(20),
	  pp. 1599-1614.
     
    
    (doi: 10.1042/BCJ20230297)
     
     
  
  
    
    Gulliver, Chloe, Huss, Sebastian, Semjonow, Axel, Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316 and Hoffmann, Ralf
  
(2023)
  
The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes.
    
    Cancers, 15(1),
	 
      262.
    
    (doi: 10.3390/cancers15010262)
    (PMID:36612262) 
    (PMCID:PMC9818961) 
  
  
    
    Gulliver, Chloe, Hoffmann, Ralf and Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316
  
(2022)
  
Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    
    International Journal of Biochemistry and Cell Biology, 147,
	 
      106230.
    
    (doi: 10.1016/j.biocel.2022.106230)
    (PMID:35609768) 
     
  
  
    
    Baillie, George S. ORCID: https://orcid.org/0000-0003-2469-6316, Gulliver, Chloe and Hoffmann, Ralf
  
(2021)
  
The enigmatic helicase DHX9 and its association with the hallmarks of cancer.
    
    Future Science OA, 7(2),
	 
      FSO650.
    
    (doi: 10.2144/fsoa-2020-0140)
    (PMID:33437516) 
    (PMCID:PMC7787180) 
  
  
van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)
    
    Byrne, Ashleigh M., Elliott, Christina ORCID: https://orcid.org/0000-0002-2838-8612, Hoffmann, Ralph and Baillie, George S. 
ORCID: https://orcid.org/0000-0003-2469-6316
  
(2015)
  
The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
    
    FEBS Letters, 589(6),
	  pp. 750-755.
     
    
    (doi: 10.1016/j.febslet.2015.02.004)
    (PMID:25680530) 
    (PMCID:PMC4346272) 
  
  
    
    Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. ORCID: https://orcid.org/0000-0003-2469-6316 and Houslay, M.D.
  
(2014)
  
The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.
    
    British Journal of Cancer, 110(5),
	  pp. 1278-1287.
     
    
    (doi: 10.1038/bjc.2014.22)